** Shares of drug developer Metsera MTSR.O rise 17.28% to $32.24 premarket
** Co says its experimental weight loss drug, MET-233i, hit up to 8.4% weight loss, on placebo adjusted basis, at 36 days in a small, early-stage trial
** MET-233i, a long-acting injectable monthly amylin analogue, is being developed as a standalone treatment and in combination with another experimental GLP-1 drug MET-097i
** The trial studied MET-233i in 80 participants with overweight or obesity without type 2 diabetes
** Up to last close, stock up 3.7% since it went public in January
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.